Get the Stockscreener App
36.71
1.55%
0.56
After Hours:
37.44
0.73
+1.99%
Rapport Therapeutics Inc stock is traded at $36.71, with a volume of 207.49K.
It is up +1.55% in the last 24 hours and up +31.86% over the past month.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
See More
Previous Close:
$36.15
Open:
$35.9
24h Volume:
207.49K
Relative Volume:
0.64
Market Cap:
$1.75B
Revenue:
-
Net Income/Loss:
$-111.48M
P/E Ratio:
-12.81
EPS:
-2.865
Net Cash Flow:
$-88.09M
1W Performance:
+8.96%
1M Performance:
+31.86%
6M Performance:
+42.40%
1Y Performance:
+282.40%
1-Day Range:
$35.41
$36.99
1-Week Range:
$33.18
$36.99
52-Week Range:
$7.73
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
36.71 | 1.73B | 0 | -111.48M | -88.09M | -2.865 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Feb-02-26 | Initiated | Wells Fargo | Overweight |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-16-25 | Initiated | Truist | Buy |
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
View All
Rapport Therapeutics Inc Stock (RAPP) Latest News
(RAPP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Th - GuruFocus
Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $357,816.00 in Stock - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 500 Shares - MarketBeat
Rapport Therapeutics Insider Sold Shares Worth $695,823, According to a Recent SEC Filing - marketscreener.com
10b5-1 insider sales reported for RAPP (NASDAQ: RAPP) in March–April 2026 - Stock Titan
Is Rapport Therapeutics Inc undervalued by DCF analysis2026 Pullbacks & Reliable Price Breakout Alerts - baoquankhu1.vn
How Investors May Respond To Rapport Therapeutics (RAPP) Phase 2a RAP-219 Data Spotlight At AAN 2026 - simplywall.st
Form 144 shows proposed 500-share sale; insider 10b5-1 trades (RAPP) - Stock Titan
Rapport Therapeutics’ Yeleswaram sells $12.6k in stock By Investing.com - Investing.com India
Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Therapeutics Inc (RAPP) - GuruFocus
Rapport Therapeutics’ Yeleswaram sells $12.6k in stock - Investing.com
Rapport Therapeutics (RAPP) CDO sells small block of shares - Stock Titan
Risk Report: Is Rapport Therapeutics Inc gaining market shareEarnings Recap Summary & AI Enhanced Trading Signals - baoquankhu1.vn
Form 144: Morgan Stanley Smith Barney (NASDAQ: RAPP) lists 360-share sale - Stock Titan
Bond Watch: What hedge funds are buying Rapport Therapeutics Inc2026 Earnings & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Earnings Risk: What are Rapport Therapeutics Incs technical support levels2026 Spike Watch & Fast Entry and Exit Trade Plans - baoquankhu1.vn
(RAPP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform? - simplywall.st
Rapport Therapeutics, Inc. (RAPP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rapport Therapeutics to present epilepsy trial data at AAN By Investing.com - Investing.com South Africa
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting - Sahm
Rapport Therapeutics to present epilepsy trial data at AAN - Investing.com
Rapport's new 8-week seizure data heads to a major neurology meeting - Stock Titan
Market Catalysts: Is Rapport Therapeutics Inc a good stock for dollar cost averaging2026 Growth vs Value & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Rapport Therapeutics COO Gault sells $281k in stock By Investing.com - Investing.com Canada
Rapport Therapeutics COO Gault sells $281k in stock - investing.com
Rapport Therapeutics Insider Sold Shares Worth $281,857, According to a Recent SEC Filing - marketscreener.com
Rapport Therapeutics (RAPP) COO sells 10,000 shares under Rule 10b5-1 plan - Stock Titan
10,000-share Rule 144 sale by RAPP (NASDAQ: RAPP) lists $278,400 value - Stock Titan
Patterns Watch: What is the cash position of Rapport Therapeutics IncMarket Sentiment Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Aug Ideas: What hedge funds are buying Rapport Therapeutics Inc2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Will Rapport Therapeutics Inc benefit from AI trendsPortfolio Gains Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Will Rapport Therapeutics' RAP-219 Deliver A Pipeline-in-a-Product Story? - RTTNews
Rapport Therapeutics (NASDAQ:RAPP) Raised to “Strong-Buy” at Truist Financial - defenseworld.net
Yeleswaram, Rapport Therapeutics chief development officer, sells $303k By Investing.com - Investing.com India
Yeleswaram, Rapport Therapeutics chief development officer, sells $303k - Investing.com
Rapport Therapeutics Insider Sold Shares Worth $303,355, According to a Recent SEC Filing - MarketScreener
Rapport Therapeutics (RAPP) CDO sells 10,115 shares under 10b5-1 plan - Stock Titan
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
All Essential Information Regarding Rapport Therapeutics, Inc. (RAPP) Rating Raised to Buy - Bitget
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy - sharewise.com
Rapport Therapeutics (NASDAQ:RAPP) Upgraded at Truist Financial - MarketBeat
RAPP (NASDAQ: RAPP) insider sale reported: 2,840 common shares - Stock Titan
Geopolitics Watch: Will Rapport Therapeutics Inc stock go up in YEAR2026 Price Targets & AI Driven Price Predictions - baoquankhu1.vn
(RAPP) Risk Channels and Responsive Allocation - Stock Traders Daily
RAPP SEC FilingsRapport Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RAPP Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Rapport Therapeutics Inc Stock (RAPP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):